| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705580 | Ophthalmology | 2016 | 7 Pages |
Abstract
To the best of our knowledge, this is the first multicenter real-world study on the incidence of blindness and sight impairment based on VA data in patients treated with ranibizumab for nAMD, and its results show low incidences of both blindness and sight impairment, which both declined during the study period.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Robert L. FRCOphth, Aaron Y. MD, MSCI, Miranda MB BChir, Richard MD, FRCOphth, Clare MD, FRCOphth, Martin FRCOphth, Usha MD, PhD, Adnan MD, FRCOphth, UK AMD EMR Users Group UK AMD EMR Users Group,